Testing effectiveness (Phase 2)Study completedNCT02594098What this trial is testingSecukinumab for Treatment of Atopic DermatitisWho this might be right forAtopic Dermatitis Icahn School of Medicine at Mount Sinai 41
Testing effectiveness (Phase 2)Study completedNCT03041038What this trial is testingThe Efficacy and Safety of Secukinumab in Patients With IchthyosesWho this might be right forIchthyosisAutosomal Recessive Congenital IchthyosisLamellar Ichthyosis+3 more Northwestern University 20
Testing effectiveness (Phase 2)Study completedNCT03568136What this trial is testingInvestigation of Efficacy of Secukinumab in Patients With Moderate to Serve Atopic DermatitisWho this might be right forDermatitis, AtopicEczema, AtopicNeurodermatitis, Atopic GWT-TUD GmbH 22
Not applicableStudy completedNCT07130331What this trial is testingEfficacy and Influencing Factors of Secukinumab in Patients With Axial SpondyloarthritisWho this might be right forAxial Spondylarthritis (axSpA)Secukinumab The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School 200
Large-scale testing (Phase 3)Study completedNCT02474082What this trial is testingStudy of Secukinumab Compared to Fumaderm® in Adults With Moderate to Severe Psoriasis.Who this might be right forPsoriasis Novartis Pharmaceuticals 202
Not applicableLooking for participantsNCT06399432What this trial is testingMediterranean Diet vs no Dietary Intervention for Improving Signs and Symptoms of Psoriasis in Patients Treated With Anti-IL-17 or Anti-IL-23 InhibitorsWho this might be right forPsoriasis University Hospitals Cleveland Medical Center 36
Large-scale testing (Phase 3)Study completedNCT03906136What this trial is testingAScalate: Treat-to-target in Axial SpondyloarthritisWho this might be right forAxial Spondyloarthritis Novartis Pharmaceuticals 304
Large-scale testing (Phase 3)Study completedNCT01892436What this trial is testingExtension Study up to 3 Years for Secukinumab in Psoriatic ArthritisWho this might be right forPsoriatic Arthritis Novartis Pharmaceuticals 460
Large-scale testing (Phase 3)Study completedNCT04102007What this trial is testingThe Safety and Efficacy of Risankizumab in Adult Participants With Plaque Psoriasis Who Have Had a Suboptimal Response to Secukinumab or IxekizumabWho this might be right forPlaque Psoriasis AbbVie 244
Testing effectiveness (Phase 2)Ended earlyNCT03791060What this trial is testingSecukinumab for NLD (Cosentyx) in Patients With Necrobiosis Lipoidica Diabeticorum (NLD)Who this might be right forNecrobiosis Lipoidica Diabeticorum Beth Israel Deaconess Medical Center 4
Testing effectiveness (Phase 2)Study completedNCT01537432What this trial is testingMultiple-dose Regimen Study to Assess Effect of 12 Months of Secukinumab Treatment on Skin Response and Biomarkers in Psoriasis PatientsWho this might be right forPsoriasis, Plaque-type Psoriasis Novartis Pharmaceuticals 36
Large-scale testing (Phase 3)Study completedNCT05569174What this trial is testingStudy of Efficacy and Safety of AIN457/Secukinumab in Patients With Rotator Cuff TendinopathyWho this might be right forTendinopathy Novartis Pharmaceuticals 62
Testing effectiveness (Phase 2)WithdrawnNCT04274166What this trial is testingSecukinumab for the Inflammatory Phase of Pyoderma GangrenosumWho this might be right forPyoderma Gangrenosum Wake Forest University Health Sciences
Testing effectiveness (Phase 2)Study completedNCT03553823What this trial is testingComparison of Secukinumab Versus Guselkumab in Clearing Psoriatic Plaques Refractory to UstekinumabWho this might be right forChronic Plaque-type Psoriasis Novartis Pharmaceuticals 40
Post-approval studies (Phase 4)Active Not RecruitingNCT05622708What this trial is testingSecukinumab to Evaluate Maintenance of Response in Participants With Non-radiographic Axial Spondyloarthritis Who Achieved RemissionWho this might be right forNon-radiographic Axial Spondyloarthritis Novartis Pharmaceuticals 240
Post-approval studies (Phase 4)Study completedNCT04080661What this trial is testingTherapeutic Drug Monitoring of Secukinumab in Psoriasis Patients.Who this might be right forPsoriasis Vulgaris University Hospital, Ghent 82
Large-scale testing (Phase 3)Study completedNCT01752634What this trial is testingEfficacy at 24 Weeks With Long Term Safety, Tolerability and Efficacy up to 5 Years of Secukinumab in Patients of Active Psoriatic ArthritisWho this might be right forPsoriatic Arthritis Novartis Pharmaceuticals 397
Post-approval studies (Phase 4)Study completedNCT03623867What this trial is testingPsA Secukinumab XCT Structural Progression StudyWho this might be right forPsoriatic Arthritis Chinese University of Hong Kong 40
Not applicableStudy completedNCT05677542What this trial is testingSecukinumab (Cosentyx®) Effectiveness in Axial Spondyloarthritis and Psoriatic Arthritis Patients Using Artificial Intelligence (SpAINET): Spanish Multicenter, Retrospective, Real World Evidence StudyWho this might be right forAxial SpondyloarthritisPsoriatic Arthritis Novartis Pharmaceuticals 758
Testing effectiveness (Phase 2)Ended earlyNCT01478360What this trial is testingSafety, Tolerability, and Efficacy of AIN457 in Patients With Uncontrolled AsthmaWho this might be right forAsthma Novartis Pharmaceuticals 46